BCL2 and lymphoma: Lymphomas with MYC and BCL2 rearrangements comprise a biologically more homogeneous group both in gene-expression profile (germinal center origin profile) and mutational profile, unlike cases with MYC and BCL6 rearrangements, which include a more heterogeneous variety of cases, including cases with “pseudo” DH where MYC rearranges with BCL6 [1,2,67] Clinical data specifically on DH-BCL6 cases are still limited, and although retrospective studies have reported variable prognosis, recent data suggest a more comparable outcome to DLBCL than to DH-BCL2 lymphoma cases [68].